ExPEC4V

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name =

| type = vaccine

| image =

| image_class =

| alt =

| caption =

| target = Escherichia coli

| vaccine_type = conjugate

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Intramuscular injection

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US =

| legal_US_comment =

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| CAS_number =

| PubChem =

| DrugBank =

| synonyms = ExPEC4-V; ExPEC-4V; ExPECV4; ExPEC-V4; JNJ-63871860; JNJ63871860

}}

ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary tract infections (UTIs) and Escherichia coli infection.{{cite web | title=JNJ 63871860 | website=AdisInsight | date=5 November 2023 | url=https://adisinsight.springer.com/drugs/800037300 | access-date=26 February 2025}}{{cite journal | vauthors = Huttner A, Gambillara V | title = The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli | journal = Clinical Microbiology and Infection | volume = 24 | issue = 10 | pages = 1046–1050 | date = October 2018 | pmid = 29803843 | doi = 10.1016/j.cmi.2018.05.009 }}{{cite journal | vauthors = Qiu L, Chirman D, Clark JR, Xing Y, Hernandez Santos H, Vaughan EE, Maresso AW | title = Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges | journal = Gut Microbes | volume = 16 | issue = 1 | pages = 2359691 | date = 2024 | pmid = 38825856 | pmc = 11152113 | doi = 10.1080/19490976.2024.2359691 }}{{cite journal | vauthors = Doiron RC, Cotechini T, Nickel JC | title = It's Time to Embrace Vaccination as We Enter the Postantibiotic Era of Recurrent Urinary Tract Infection Management | journal = The Journal of Urology | volume = 211 | issue = 6 | pages = 797–799 | date = June 2024 | pmid = 38704743 | doi = 10.1097/JU.0000000000003969 }} It is an Escherichia coli polysaccharide conjugate vaccine. The vaccine is admnistered by intramuscular injection. It is being developed by GlycoVaxyn and Johnson & Johnson. As of November 2023, ExPEC4V is in phase 2 clinical trials. There is also a 10-valent form called ExPEC10V (VAC-52416; JNJ-69968054).{{cite web | title=VAC 52416 | website=AdisInsight | date=28 April 2023 | url=https://adisinsight.springer.com/drugs/800053991 | access-date=26 February 2025}}